Short answer
Teleflex Inc (TFX) filed its Q3 2019 10-Q quarterly report on Oct 31, 2019 for the quarter ended Sep 29, 2019.
Teleflex Inc Q3 2019 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $648.3M, up 6.3% YoY from $609.7M, driven by existing-product volume growth of $35.1M
- Gross margin 57.9% vs 56.2% YoY, up 170 basis points
- Best segment Americas revenue $374.5M, up 10.6%; worst EMEA revenue $140.5M, up 0.7%
- Operating cash flow $289.2M year-to-date vs $302.9M, with $83.8M capital expenditures
- Sterigenics disruption expected to reduce fourth-quarter revenue by approximately $9M, with potential 2020 impact
Risk Factors
- New risk triggered by Sterigenics Smyrna suspension, sterilization disruptions impairing affected product availability
- Regulatory risk: Georgia EPD testing and Cobb County permit actions continued facility suspension
- Near-term operating impact: approximately $9 million revenue reduction in fourth-quarter 2019
- Capacity risk: FDA requirements and constraints may delay alternate sterilization facilities
- Compliance risk: 15 state attorneys general and District of Columbia urged stricter EPA ethylene oxide standards
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Teleflex Inc quarterly reports
- Q2 2019 10-QFiled Aug 1, 2019
- Q1 2019 10-QFiled May 2, 2019
- Q3 2018 10-QFiled Nov 1, 2018
- Q3 2018 10-QFiled Aug 2, 2018
- Q2 2018 10-QFiled May 3, 2018
- Q4 2017 10-QFiled Nov 2, 2017
- Q3 2017 10-QFiled Aug 3, 2017
- Q2 2017 10-QFiled May 4, 2017
- Q3 2016 10-QFiled Oct 27, 2016
- Q2 2016 10-QFiled Jul 28, 2016
- Q1 2016 10-QFiled Apr 28, 2016
- Q3 2015 10-QFiled Oct 29, 2015
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.